Therapeutics News and Research

RSS

Larger trial study needed to decide fate of niacin

Niaspan is a cholesterol drug manufactured by Abbott Laboratories. Doctors have customarily prescribed Niacin to raise levels of HDL ("good" cholesterol) in patients taking a statin pill that is successfully lowering their LDL ("bad" cholesterol).

10 Jun 2011

Revance closes $45 million financing

Revance Therapeutics, Inc. today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital.

10 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

The Scripps Research Institute has been awarded a $2.2 million grant from the National Institutes of Health (NIH) to develop novel therapeutics for the treatment of addiction to multiple substances in a national effort with the University of Kansas.

10 Jun 2011

Respira introduces breakthrough Dry Powder Inhaler

Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, introduces the company's Dry Powder Inhaler (DPI) as a breakthrough solution for the pharmaceutical industry. Based on proprietary drug engine technology (DET), Respira Therapeutics' DPI significantly improves therapeutic performance and enables addressing the unmet medical needs of patients with severe respiratory diseases.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

9 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

Article reports on bright future and enormous need for stem cell therapeutics

An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.

9 Jun 2011

Skin cell-derived CGRP-beta may cause chronic pain

A new study may explain why only 50% of patients experiencing chronic nerve pain achieve even partial relief from existing therapeutics. The study, published in the June 6 online version of the international research journal PAIN, reveals that certain types of chronic pain may be caused by signals from the skin itself, rather than damage to nerves within the skin, as previously thought.

9 Jun 2011

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists at Rockefeller University and The Scripps Research Institute have developed the first genetically humanized mouse model for hepatitis C, an achievement that will enable researchers to test molecules that block entry of the hepatitis C virus into cells as well as potential vaccine candidates. The finding is reported in the June 9 issue of the journal Nature.

9 Jun 2011

Scientists, advocacy experts form new international Foundation for Vaccine Research

Fourteen leading scientists and advocacy experts in vaccines and infectious diseases have announced the formation of a new international Foundation to advance and accelerate vaccine research and development against infectious diseases.

9 Jun 2011

ACT's TEMPASURE cardiac ablation catheter receives CE Mark

Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that the company has received CE Mark (Conformité Européenne) clearance for its TEMPASURE™ cardiac ablation catheter. The TEMPASURE system is the world's first RF cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology.

8 Jun 2011

New journal on multiple sclerosis and related disorders

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new journal, Multiple Sclerosis and Related Disorders with its first issue publication in January 2012.

8 Jun 2011

Closed-loop artificial pancreas could fight against Type 1 diabetes

Engineering researchers at Rensselaer Polytechnic Institute are combining automation techniques from oil refining and other diverse areas to help create a closed-loop artificial pancreas. The device will automatically monitor blood sugar levels and administer insulin to patients with Type 1 diabetes, and aims to remove much of the guesswork for those living with the chronic disease.

8 Jun 2011

Patient enrollment complete in BioMimetic's Augment Rotator Cuff pilot trial

BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.

8 Jun 2011

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Cyterix Pharmaceutics, Inc. announced today that the company has raised $9.2 million in a Series A financing from The Column Group and SV Life Sciences. Cyterix is developing novel cancer therapeutics based on a prodrug approach that targets extra-hepatic cytochrome P450 enzymes that are over-expressed in many cancers to a high frequency, but not in normal tissues.

7 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

Therapeutics News and Research

Larger trial study needed to decide fate of niacin

Revance closes $45 million financing

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

Respira introduces breakthrough Dry Powder Inhaler

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Article reports on bright future and enormous need for stem cell therapeutics

Skin cell-derived CGRP-beta may cause chronic pain

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists, advocacy experts form new international Foundation for Vaccine Research

ACT's TEMPASURE cardiac ablation catheter receives CE Mark

New journal on multiple sclerosis and related disorders

Closed-loop artificial pancreas could fight against Type 1 diabetes

Patient enrollment complete in BioMimetic's Augment Rotator Cuff pilot trial

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News